Aurinia Pharmaceuticals Inc.
NASDAQ · AUPH·Edmonton, Canada·Small-cap·Approved
Autoimmune-focused biopharma commercializing LUPKYNIS (voclosporin), the first oral therapy approved for active lupus nephritis, generating $305-315M in guided 2026 sales. Pipeline centers on aritinercept (AUR200), a dual BAFF/APRIL inhibitor with Phase 1 data showing up to 55% IgM reduction.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Aurinia Corporate Presentation February 2026 | Corporate overview | February 1, 2026 | 31 |